Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum.
Smeaton LM, Kileel EM, Grinsztejn B, Gardner EM, Starr K, Murry ML, Desvigne-Nickens P, Alston-Smith B, Waclawiw MA, Cooper-Arnold K, Madruga JV, Sangle S, Fitch KV, Zanni MV, Douglas PS, Ribaudo HJ, Grinspoon SK, Klingman KL.
Smeaton LM, et al. Among authors: sangle s.
J Infect Dis. 2020 Jul 9;222(Suppl 1):S31-S40. doi: 10.1093/infdis/jiaa213.
J Infect Dis. 2020.
PMID: 32645160
Free PMC article.
Clinical Trial.